R5655

Rebamipide hydrate

≥98% (HPLC), powder

• Sinónimos: α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid hydrate, Mucosta hydrate, OPC 12759 hydrate, Proamipide hydrate
• Fórmula empírica (notación de Hill): C₁₉H₁₅ClN₂O₄ · xH₂O
• Número de CAS: 90098-04-7
• Peso molecular: 370.79 (anhydrous basis)
• MDL number: MFCD11114396
• UNSPSC Code: 12352200
• PubChem Substance ID: 329824033
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white
• solubility: DMSO: >5 mg/mL
• SMILES string: O.OC(=O)C(CC1=CC(=O)Nc2ccccc12)NC(=O)c3ccc(Cl)cc3
• InChI: 1S/C19H15ClN2O4.H2O/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15;/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26);1H2
• InChI key: WQRHVBKNEDPECA-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

Rebamipide is an anti-ulcer agent with free-radical scavenging and anti-inflammatory effects. It has been used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating COX-2 genes. Rebamipide significantly reduced ulcerogenesis and maintained mucosal superoxide dismutase (SOD) activity. It has also been used for the treatment of Behçet′s disease. Rebamipide may be involved in a noval mechanism to enhance tear secretion and increase mucin levels covering conjunctiva and cornea.

Rebamipide helps to reduce intestinal injury, stimulated by radiation.

Información de seguridad

• pictograms: GHS06
• signalword: Danger
• hcodes: H301
• pcodes: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral
• Storage Class: 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Faceshields, Gloves, type N95 (US)